{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:27:44Z","timestamp":1787149664503,"version":"build-2736575974"},"reference-count":26,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"unspecified","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Health Education England\/NIHR","award":["Academic Clinical Lecturer"],"award-info":[{"award-number":["Academic Clinical Lecturer"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2026,7,10]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Risankizumab is an interleukin-23 p19 subunit inhibitor, which gained UK approval in May 2023 for the treatment of Crohn\u2019s disease. Our aim was to evaluate risankizumab use in a real-world Crohn\u2019s disease cohort across North West England.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ARISE-CD is a retrospective, multicentre cohort study of adults with Crohn\u2019s disease across nine hospitals in North West England between May 2024 and April 2025. The primary outcome was treatment persistence at 6 months. Secondary outcomes included steroid-free persistence; steroid-free clinical remission (Crohn\u2019s Disease Activity Index (CDAI) &lt;150\u2009or Harvey Bradshaw Index (HBI) &lt;5), biochemical remission (C-reactive protein (CRP) \u22645\u2009mg\/L and faecal calprotectin \u2264250\u2009\u00b5g\/g) and reporting of adverse events. The cohort was also stratified by prior ustekinumab exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>131 patients were included. All patients started risankizumab at least 6 months prior to data collection, with a median of 41 weeks (34\u201352) follow-up and a median of 2 (1\u20133) prior advanced therapies. 90% had exposure to prior anti-tumour necrosis factor therapy and 56% had been exposed to ustekinumab therapy. 6-month treatment persistence was 91% and 6-month steroid-free persistence was 84%. There was no difference in treatment persistence stratified by prior ustekinumab exposure. At 6 months, 14 out of 21 (67%) patients were in steroid-free clinical remission, and 15 out of 40 (38%) patients were in biochemical remission. In patients with paired results at baseline and 6 months, there was a significant reduction in median CRP (6\u2009mg\/L vs 4\u2009mg\/L, p=0.002) and median faecal calprotectin (201\u2009\u00b5g\/g vs 141\u2009\u00b5g\/g, p=0.001) at week 24. Prior ustekinumab exposure did not impact rates of steroid-free clinical remission or biochemical remission. No new safety signals were noted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Risankizumab was effective in a multicentre, real-world cohort of patients with Crohn\u2019s disease, both with and without prior ustekinumab exposure. No new safety signals were noted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2026-002320","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:55:23Z","timestamp":1787147723000},"page":"e002320","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of risankizumab use in adults with Crohn\u2019s disease in a real-world setting (ARISE-CD): a multicentre, retrospective cohort study"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0918-6713","authenticated-orcid":false,"given":"Thomas D","family":"Butler","sequence":"first","affiliation":[{"name":"Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK"},{"name":"Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Beard","sequence":"additional","affiliation":[{"name":"Lancashire Teaching Hospitals NHS Trust, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abosede","family":"Ososanya","sequence":"additional","affiliation":[{"name":"Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Parr","sequence":"additional","affiliation":[{"name":"Blackpool Victoria Hospital, Blackpool teaching Hospitals NHS Foundation Trust, Blackpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Kwok","sequence":"additional","affiliation":[{"name":"Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hibest","family":"Fekadu","sequence":"additional","affiliation":[{"name":"Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8850-296X","authenticated-orcid":false,"given":"Faris","family":"Chater","sequence":"additional","affiliation":[{"name":"Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Villa","family":"Kakosa","sequence":"additional","affiliation":[{"name":"Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Morgan","sequence":"additional","affiliation":[{"name":"Stockport NHS Foundation Trust, Stockport, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bonnar","sequence":"additional","affiliation":[{"name":"Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Kemp","sequence":"additional","affiliation":[{"name":"Manchester University NHS Foundation Trust, Manchester, UK"},{"name":"Faculty of Biology, Medicine and Health (Manchester Academic Health Science Centre), The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Nixon","sequence":"additional","affiliation":[{"name":"Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kneebone","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Bolton NHS Foundation Trust, Bolton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-1747","authenticated-orcid":false,"given":"Anish","family":"Kuriakose Kuzhiyanjal","sequence":"additional","affiliation":[{"name":"Northern Care Alliance NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Ormerod","sequence":"additional","affiliation":[{"name":"Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1686-4490","authenticated-orcid":false,"given":"Paul P","family":"Knight","sequence":"additional","affiliation":[{"name":"Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinor","family":"Shuttleworth","sequence":"additional","affiliation":[{"name":"Lancashire Teaching Hospitals NHS Trust, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys","family":"Butcher","sequence":"additional","affiliation":[{"name":"Blackpool Victoria Hospital, Blackpool teaching Hospitals NHS Foundation Trust, Blackpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Chatten","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Bolton NHS Foundation Trust, Bolton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Crooks","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Bolton NHS Foundation Trust, Bolton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy K","family":"Limdi","sequence":"additional","affiliation":[{"name":"Faculty of Biology, Medicine and Health (Manchester Academic Health Science Centre), The University of Manchester, Manchester, UK"},{"name":"Northern Care Alliance NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"White","sequence":"additional","affiliation":[{"name":"Stockport NHS Foundation Trust, Stockport, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026081906551499000_13.1.e002320.1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-079050","article-title":"Medical management of inflammatory bowel diseases","volume":"391","author":"Hashash","year":"2025","journal-title":"BMJ"},{"key":"2026081906551499000_13.1.e002320.2","unstructured":"National Institute for Clinical Excellence . Risankizumab for previously treated moderately to severely active Crohn\u2019s disease. 2023. Available: https:\/\/www.nice.org.uk\/guidance\/ta888"},{"key":"2026081906551499000_13.1.e002320.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00467-6"},{"key":"2026081906551499000_13.1.e002320.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00466-4"},{"key":"2026081906551499000_13.1.e002320.5","first-page":"1583","article-title":"A Core Outcome Set for Inflammatory Bowel Diseases: Development and Recommendations for Implementation in Clinical Practice Through an International Multi-stakeholder Consensus Process","volume":"18","author":"Fierens","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026081906551499000_13.1.e002320.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"2026081906551499000_13.1.e002320.7","unstructured":"Kassambara AK , Biecek M . survminer: Drawing Survival Curves using \u2019ggplot2. 2025."},{"key":"2026081906551499000_13.1.e002320.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314585"},{"key":"2026081906551499000_13.1.e002320.9","doi-asserted-by":"crossref","DOI":"10.4292\/wjgpt.v16.i4.110273","article-title":"Risankizumab is effective following ustekinumab failure in Crohn\u2019s disease: A real-world study from a tertiary center","volume":"16","author":"Colwill","year":"2025","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"2026081906551499000_13.1.e002320.10","doi-asserted-by":"crossref","unstructured":"Johnson AM , Askar M , Belani S , et al . A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn\u2019s disease. Journal of Crohn\u2019s and Colitis 2025;19. doi:10.1093\/ecco-jcc\/jjaf070","DOI":"10.1093\/ecco-jcc\/jjaf070"},{"key":"2026081906551499000_13.1.e002320.11","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.cgh.2024.09.027","article-title":"Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn\u2019s Disease","volume":"23","author":"Zinger","year":"2025","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"2026081906551499000_13.1.e002320.12","unstructured":"Greater Manchester Medicines Management Group . High cost drugs pathways for inflammatory bowel disease in adults. 2023. Available: https:\/\/gmmmg.nhs.uk"},{"key":"2026081906551499000_13.1.e002320.13","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1093\/ibd\/izaf162","article-title":"Long-term Outcomes of Patients with Crohn\u2019s Disease Treated with Risankizumab","volume":"31","author":"Geeganage","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026081906551499000_13.1.e002320.14","doi-asserted-by":"crossref","unstructured":"Elford AT , Constantine-Cooke N , Shah K , et al . Real-world effectiveness of risankizumab in Crohn\u2019s disease: a pan UK retrospective cohort study. Frontline Gastroenterol 2026;flgastro\u20132025. doi:10.1136\/flgastro-2025-103449","DOI":"10.1136\/flgastro-2025-103449"},{"key":"2026081906551499000_13.1.e002320.15","doi-asserted-by":"crossref","unstructured":"Scaldaferri F , Di Vincenzo F , Aloi M , et al . Multicenter Real-World Outcomes of Risankizumab in Crohn\u2019s Disease: The RESOLVE IG-IBD Study. Am J Gastroenterol 2026. doi:10.14309\/ajg.0000000000003969","DOI":"10.1093\/ecco-jcc\/jjaf231.1195"},{"key":"2026081906551499000_13.1.e002320.16","unstructured":"Office for National Statistics . Population of England and Wales. 2022. Available: https:\/\/www.ethnicity-facts-figures.service.gov.uk\/uk-population-by-ethnicity"},{"key":"2026081906551499000_13.1.e002320.17","unstructured":"Greater Manchester Combined Authority . Census 2021 briefing. 2023. Available: https:\/\/www.greatermanchester-ca.gov.uk\/media\/8089\/census-2021-briefing_ethnicity_final-v5.pdf"},{"key":"2026081906551499000_13.1.e002320.18","doi-asserted-by":"crossref","unstructured":"Balarajah S , Martinez-Gili L , Alexander JL , et al . Diverse Phenotypes, Consistent Treatment: A Study of 30\u2005997 South Asian and White Inflammatory Bowel Disease Patients Using the UK Inflammatory Bowel Disease BioResource. Journal of Crohn\u2019s and Colitis 2025;19. doi:10.1093\/ecco-jcc\/jjae186","DOI":"10.1093\/ecco-jcc\/jjae186"},{"key":"2026081906551499000_13.1.e002320.19","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2013-304907.385","article-title":"PWE-097\u2005The Effect of Ethnicity on the Prevalence of Inflammatory Bowel Disease with the Luton and Dunstable Catchment Region, in UK","volume":"62","author":"Johnson","year":"2013","journal-title":"Gut"},{"key":"2026081906551499000_13.1.e002320.20","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S2468-1253(23)00193-0","article-title":"Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review","volume":"8","author":"Pathiyil","year":"2023","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"2026081906551499000_13.1.e002320.21","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/ibd\/izae077","article-title":"Inequalities in Healthcare Access, Experience and Outcomes in Adults With Inflammatory Bowel Disease: A Scoping Review","volume":"30","author":"Hawkins","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026081906551499000_13.1.e002320.22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41575-025-01038-y","article-title":"Influence of biological sex in inflammatory bowel diseases","volume":"22","author":"Tshikudi","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026081906551499000_13.1.e002320.23","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13020165","article-title":"Impact of Female Gender in Inflammatory Bowel Diseases: A Narrative Review","volume":"13","author":"Lungaro","year":"2023","journal-title":"J Pers Med"},{"key":"2026081906551499000_13.1.e002320.24","unstructured":"Getting It Right First Time . Optimising care for patients with inflammatory bowel disease (IBD). 2025. Available: https:\/\/gettingitrightfirsttime.co.uk"},{"key":"2026081906551499000_13.1.e002320.25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects","volume":"13","author":"Sturm","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026081906551499000_13.1.e002320.26","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.gie.2019.11.032","article-title":"A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos)","volume":"91","author":"Limdi","year":"2020","journal-title":"Gastrointest Endosc"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2026-002320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:55:26Z","timestamp":1787147726000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2026-002320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,8,19]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bmjgast-2026-002320"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2026-002320","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}